Month: November 2021

With the increasing global population, the incidence rates of several chronic disease indications, such as diabetes, heart disorders, neurological disorders and oncological disorders, are on the rise. This has led to a rise in the demand for effective treatment options for patients suffering from these diseases. Further, in order to improve the quality of life

Over the years, advances in drug / therapy development processes have led the pharmaceutical industry to gradually shift from a one-drug treats all model to a more personalized approach of treatment. The growing complexity of modern pharmacological interventions, such as monoclonal antibodies, and cell and gene therapies, has further prompted the drug developers to develop

Since the approval of Enbrel®, CD4-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics.[1] Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion therapeutics including  Arcalyst® (recurrent pericarditis,

Primary packaging material (e.g. Pharmaceutical Vials) plays a crucial role in preserving the stability, efficacy and safety of the drug as it is in direct contact with the packaged therapeutic. Additionally, primary packaging material assists in maintaining the sterility and quality of a drug product, while also providing information related to its identity and, in

Antibody-drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have captured the attention of both large and small pharmaceutical companies, and academic / research institutions from all across the world. Fundamentally, these complex biotherapeutic entities demonstrate the combination of target specificity of an antibody and therapeutic features of a chemotherapy / cytotoxic

With close to 100 approved monoclonal antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fast growing segment of the biopharmaceutical industry.[1] In fact, these interventions are anticipated to generate a cumulative sales of USD 300 billion by 2025.[2] Further, within the antibody therapeutics industry, engineered

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. ADC Therapeutics are engineered therapies comprised of monoclonal antibodies